10 research outputs found
A comparison of EyeSeeCam VOG<sup>®</sup> and ICS Impulse<sup>®</sup> in video headimpulse tests (vHIT) of the lateral semicircular canal
Sparse Coding Super-Resolution Scheme for Chest Computed Tomography
High-resolution chest computed tomography images now has a great importance in the diagnosis. However, this modality requires using a higher radiation dose and a longer scanning time compared to low-resolution computed tomography. In this study, we applied the sparse coding super-resolution method to reconstruct high-resolution images without increasing the radiation dose. We prepared an over-complete dictionary by mapping between low- and high-resolution patches and represented this as a sparse linear combination of each patch of the low-resolution input. These coefficients were used to reconstruct the high-resolution output. In our experiments, 89 computed tomography scans were analyzed. We up-sampled the images 2 or 4 times and compared the image quality of the sparse coding super-resolution scheme with those of the nearest neighbor and bilinear interpolations, which are the traditional interpolation schemes. The image quality was evaluated by measuring the peak signal-to-noise ratio and structure similarity. The differences in the peak signal-to-noise ratios and structure similarities between the sparse coding super-resolution method and the nearest neighbor or bilinear method were statistically significant. Visual assessment confirmed that the sparse coding super-resolution method generated high-resolution images, whereas the conventional interpolation methods generated over-smoothed images. Taken together, these results suggest that the sparse coding super-resolution approach is a robust method for up-sampling computed tomography images and that it yields images with markedly high resolution when magnifying chest computed tomography scans
Regiocontrolled Oxidative Coupling Polycondensation of 2,5-Dimethylphenol Induced by Mesoporous Interior
Identification of Bitterness-Masking Compounds from Cheese
Bitterness-masking compounds were identified in a natural
white
mold cheese. The oily fraction of the cheese was extracted and further
fractionated by using silica gel column chromatography. The four fractions
obtained were characterized by thin-layer chromatography and nuclear
magnetic resonance spectroscopy. The fatty acid-containing fraction
was found to have the highest bitterness-masking activity against
quinine hydrochloride. Bitterness-masking activity was quantitated
using a method based on subjective equivalents. At 0.5 mM, the fatty
acid mixture, which had a composition similar to that of cheese, suppressed
the bitterness of 0.008% quinine hydrochloride to be equivalent to
that of 0.0049–0.0060% and 0.5 mM oleic acid to that of 0.0032–0.0038%
solution. The binding potential between oleic acid and the bitter
compounds was estimated by isothermal titration calorimetry. These
results suggest that oleic acid masked bitterness by forming a complex
with the bitter compounds
Genetic Evidence for the Role of a Rice Vacuolar Invertase as a Molecular Sink Strength Determinant
Nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy in 2008: general view of the pathogens’ antibacterial susceptibility
Edoxaban versus warfarin in patients with atrial fibrillation
Contains fulltext :
125374.pdf (publisher's version ) (Open Access)BACKGROUND: Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known. METHODS: We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding. RESULTS: The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban (hazard ratio, 1.07; 97.5% CI, 0.87 to 1.31; P=0.005 for noninferiority). In the intention-to-treat analysis, there was a trend favoring high-dose edoxaban versus warfarin (hazard ratio, 0.87; 97.5% CI, 0.73 to 1.04; P=0.08) and an unfavorable trend with low-dose edoxaban versus warfarin (hazard ratio, 1.13; 97.5% CI, 0.96 to 1.34; P=0.10). The annualized rate of major bleeding was 3.43% with warfarin versus 2.75% with high-dose edoxaban (hazard ratio, 0.80; 95% CI, 0.71 to 0.91; P<0.001) and 1.61% with low-dose edoxaban (hazard ratio, 0.47; 95% CI, 0.41 to 0.55; P<0.001). The corresponding annualized rates of death from cardiovascular causes were 3.17% versus 2.74% (hazard ratio, 0.86; 95% CI, 0.77 to 0.97; P=0.01), and 2.71% (hazard ratio, 0.85; 95% CI, 0.76 to 0.96; P=0.008), and the corresponding rates of the key secondary end point (a composite of stroke, systemic embolism, or death from cardiovascular causes) were 4.43% versus 3.85% (hazard ratio, 0.87; 95% CI, 0.78 to 0.96; P=0.005), and 4.23% (hazard ratio, 0.95; 95% CI, 0.86 to 1.05; P=0.32). CONCLUSIONS: Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.)